Find therapies in clinical trials near you – page 7

Study on Safe Skin Test Concentrations for Biotherapy Allergies in Patients with Cancer Using Atezolizumab, Daratumumab, and Nivolumab

Study on Safe Skin Test Concentrations for Biotherapy Allergies in Patients with Cancer Using Atezolizumab, Daratumumab, and Nivolumab

Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Study Comparing Rilvegostomig with Fluoropyrimidine and Trastuzumab Deruxtecan to Standard Treatment for Patients with HER2-positive Gastric Cancer

Study Comparing Rilvegostomig with Fluoropyrimidine and Trastuzumab Deruxtecan to Standard Treatment for Patients with HER2-positive Gastric Cancer

Study on Pembrolizumab and Drug Combination for Patients with Recurrent Head and Neck Cancer

Study on Pembrolizumab and Drug Combination for Patients with Recurrent Head and Neck Cancer

Study of Pembrolizumab with Cisplatin or Carboplatin and Etoposide for Patients with Advanced Merkel Cell Carcinoma

Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Study of HLX22, Trastuzumab, and Chemotherapy for Patients with Advanced or Metastatic Stomach and Gastroesophageal Cancer

Study of HLX22, Trastuzumab, and Chemotherapy for Patients with Advanced or Metastatic Stomach and Gastroesophageal Cancer

Study on IMA203 for Patients with Previously Treated Unresectable or Metastatic Skin Melanoma

Study on IMA203 for Patients with Previously Treated Unresectable or Metastatic Skin Melanoma

Study of Patritumab Deruxtecan and Pembrolizumab for Patients with High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive Breast Cancer

Study of Patritumab Deruxtecan and Pembrolizumab for Patients with High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive Breast Cancer

Study of ALE.P02 for Adults with Advanced or Metastatic Squamous Solid Tumors

Study of ALE.P02 for Adults with Advanced or Metastatic Squamous Solid Tumors

Study of Ifinatamab Deruxtecan and Pembrolizumab, With or Without Chemotherapy, for Patients With Untreated Advanced Esophageal Cancer

Study of Ifinatamab Deruxtecan and Pembrolizumab, With or Without Chemotherapy, for Patients With Untreated Advanced Esophageal Cancer

Study on the Safety and Effects of BMS-986507 with Pembrolizumab and Osimertinib Mesylate in Adults with Advanced Solid Tumors

Study on the Safety and Effects of BMS-986507 with Pembrolizumab and Osimertinib Mesylate in Adults with Advanced Solid Tumors